{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:48:28Z","timestamp":1789674508066,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.msard.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T21:36:31Z","timestamp":1516138591000},"page":"93-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Biomarkers identification for PML monitoring, during Natalizumab (Tysabri\u00ae) treatment in Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.1016","volume":"20","author":[{"given":"Veronica","family":"Lanza Cariccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Placido","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Mazzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2018.01.011_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/excr.2000.4941","article-title":"Analysis of the alpha4beta1 integrin-osteopontin interaction","volume":"258","author":"Barry","year":"2000","journal-title":"Exp. Cell Res."},{"issue":"4","key":"10.1016\/j.msard.2018.01.011_bib2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/PAT.0b013e3283463558","article-title":"Immunosuppression increases latent infection of brain by JC polyomavirus","volume":"43","author":"Bayliss","year":"2011","journal-title":"Pathology"},{"issue":"20","key":"10.1016\/j.msard.2018.01.011_bib3","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2018.01.011_bib4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.173.6.1553","article-title":"Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules","volume":"173","author":"Bochner","year":"1991","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.msard.2018.01.011_bib5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2018.01.011_bib6","first-page":"78","article-title":"Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with Natalizumab: baseline results of STRATIFY-2","author":"Bozic","year":"2012","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2018.01.011_bib7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2018.01.011_bib8","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/eji.1830211132","article-title":"Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation","volume":"21","author":"Burkly","year":"1991","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2018.01.011_bib9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s13365-016-0482-z","article-title":"Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV(R) DxSelect antibody assay","volume":"22","author":"Campagnolo","year":"2016","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.msard.2018.01.011_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneuroim.2017.05.006","article-title":"CD4\/CD8 ratio during natalizumab treatment in multiple sclerosis patients","volume":"309","author":"Carotenuto","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2018.01.011_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.05.017","article-title":"Cloning of the first human anti-JCPyV\/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy","volume":"108","author":"Diotti","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.msard.2018.01.011_bib12","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/brain\/awh215","article-title":"A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy","volume":"127","author":"Du Pasquier","year":"2004","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.msard.2018.01.011_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.it.2005.07.004","article-title":"The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms","volume":"26","author":"Engelhardt","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.msard.2018.01.011_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-biochem-060308-103103","article-title":"Regulation of mRNA translation and stability by microRNAs","volume":"79","author":"Fabian","year":"2010","journal-title":"Annu. Rev. Biochem."},{"issue":"3","key":"10.1016\/j.msard.2018.01.011_bib15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"issue":"14","key":"10.1016\/j.msard.2018.01.011_bib16","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1128\/JVI.02506-10","article-title":"Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome","volume":"85","author":"Gheuens","year":"2011","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.msard.2018.01.011_bib17","first-page":"995","article-title":"Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: the role of natalizumab","volume":"3","author":"Ghosh","year":"2003","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2018.01.011_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0092-8674(90)90715-Q","article-title":"Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1","volume":"60","author":"Guan","year":"1990","journal-title":"Cell"},{"issue":"1\u20132","key":"10.1016\/j.msard.2018.01.011_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jneuroim.2011.03.001","article-title":"Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells","volume":"234","author":"Harrer","year":"2011","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"10.1016\/j.msard.2018.01.011_bib20","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1128\/JVI.00131-13","article-title":"Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy","volume":"87","author":"Hendel-Chavez","year":"2013","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.msard.2018.01.011_bib21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.01.011_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1371\/journal.pone.0160277","article-title":"Natalizumab affects T-Cell phenotype in multiple sclerosis: implications for JCV reactivation","volume":"11","author":"Iannetta","year":"2016","journal-title":"Plos One"},{"issue":"4","key":"10.1016\/j.msard.2018.01.011_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.msard.2018.01.011_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/0-387-32957-9_2","article-title":"Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV)","volume":"577","author":"Knowles","year":"2006","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.msard.2018.01.011_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","article-title":"Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40","volume":"71","author":"Knowles","year":"2003","journal-title":"J. Med Virol."},{"issue":"6","key":"10.1016\/j.msard.2018.01.011_bib26","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1099\/vir.0.79903-0","article-title":"Cytokine production by virus-specific CD8+ T cells varies with activation state and localization, but not with TCR avidity","volume":"85","author":"Kristensen","year":"2004","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.msard.2018.01.011_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2018.01.011_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J. Clin. Virol."},{"issue":"7","key":"10.1016\/j.msard.2018.01.011_bib29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00439-014-1434-4","article-title":"The impact of microRNA expression on cellular proliferation","volume":"133","author":"Lenkala","year":"2014","journal-title":"Hum. Genet"},{"issue":"9","key":"10.1016\/j.msard.2018.01.011_bib30","article-title":"CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients (vol 86, pg 375, 2016)","volume":"87","author":"Lieberman","year":"2016","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.msard.2018.01.011_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2007.11.007","article-title":"Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients","volume":"194","author":"Lindberg","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"19","key":"10.1016\/j.msard.2018.01.011_bib32","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","article-title":"Determinants of survival in progressive multifocal leukoencephalopathy","volume":"73","author":"Marzocchetti","year":"2009","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2018.01.011_bib33","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1352458514524998","article-title":"MiR-126: a novel route for natalizumab action?","volume":"20","author":"Meira","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.01.011_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1212\/NXI.0000000000000223","article-title":"Natalizumab-induced POU2AF1\/Spi-B upregulation A possible route for PML development","volume":"3","author":"Meira","year":"2016","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2018.01.011_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.msard.2018.01.011_bib36","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1177\/1352458514534513","article-title":"Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","volume":"20","author":"Munoz-Culla","year":"2014","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2018.01.011_bib37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1750-3639.2007.00120.x","article-title":"MicroRNAs (miRNAs) in neurodegenerative diseases","volume":"18","author":"Nelson","year":"2008","journal-title":"Brain Pathol."},{"issue":"1","key":"10.1016\/j.msard.2018.01.011_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"O'Connor","year":"2014","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2018.01.011_bib39","doi-asserted-by":"crossref","first-page":"e1003014","DOI":"10.1371\/journal.ppat.1003014","article-title":"Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Perkins","year":"2012","journal-title":"PLoS Pathog."},{"issue":"23","key":"10.1016\/j.msard.2018.01.011_bib40","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1212\/WNL.0000000000003401","article-title":"Cd62l test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy","volume":"87","author":"Pignolet","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2018.01.011_bib41","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2018.01.011_bib42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.msard.2018.01.011_bib43","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.01.011_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12935-015-0185-1","article-title":"MicroRNA (miRNA) in cancer","volume":"15","author":"Reddy","year":"2015","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.msard.2018.01.011_bib45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir256","article-title":"Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients","volume":"204","author":"Reid","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.msard.2018.01.011_bib46","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","article-title":"Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale","volume":"64","author":"Rice","year":"2005","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2018.01.011_bib47","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2018.01.011_bib48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/1074-7613(95)90051-9","article-title":"Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines","volume":"2","author":"Sad","year":"1995","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.msard.2018.01.011_bib49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2018.01.011_bib50","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1177\/1352458515607651","article-title":"PML risk stratification using anti-JCV antibody index and L-selectin","volume":"22","author":"Schwab","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"12","key":"10.1016\/j.msard.2018.01.011_bib51","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1182\/blood-2006-01-030015","article-title":"MicroRNAs: regulators of gene expression and cell differentiation","volume":"108","author":"Shivdasani","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.msard.2018.01.011_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clim.2012.04.002","article-title":"Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects","volume":"144","author":"Sievers","year":"2012","journal-title":"Clin. Immunol."},{"issue":"14","key":"10.1016\/j.msard.2018.01.011_bib53","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1177\/1352458513490542","article-title":"Differential microRNA expression in blood in multiple sclerosis","volume":"19","author":"Sondergaard","year":"2013","journal-title":"Mult. Scler"},{"key":"10.1016\/j.msard.2018.01.011_bib54","first-page":"12","article-title":"Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells","author":"Spadaro","year":"2015","journal-title":"J. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2018.01.011_bib55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archneur.64.2.169","article-title":"Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions","volume":"64","author":"Stuve","year":"2007","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2018.01.011_bib56","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.coph.2009.05.003","article-title":"microRNAs and the immune response","volume":"9","author":"Tsitsiou","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"issue":"4","key":"10.1016\/j.msard.2018.01.011_bib57","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2018.01.011_bib58","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","article-title":"Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Warnke","year":"2014","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2018.01.011_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1631\/jzus.B1200292","article-title":"MicroRNAs in the regulation of immune response against infections","volume":"14","author":"Zhang","year":"2013","journal-title":"J. Zhejiang Univ. Sci. B"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818300191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818300191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:41:33Z","timestamp":1761900093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818300191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":59,"alternative-id":["S2211034818300191"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.01.011","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers identification for PML monitoring, during Natalizumab (Tysabri\u00ae) treatment in Relapsing-Remitting Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}